MetaCap

Pulmonx Corporation (LUNG)

NASDAQ: LUNGHealth CareMedical/Dental InstrumentsUSD

2.57-0.17 (-6.20%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LUNG stock chart

Technical analysis

Key statistics

All statistics
Market cap
$111.93M
EPS (TTM)
-$1.01
52-week range
1.13 – 3.25
Day range
2.51 – 2.81
Volume / Avg
933.29K / 641.52K
Beta
—

52-week range

$1.13$3.25

LUNG stock today

Shares of Pulmonx (LUNG) finished lower on Nov 20 at $2.57, a drop of 6.20% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, LUNG sits in the middle of its 52-week range of $1.13 to $3.25: 20.9% below the high, set on Oct 29, 2026 and 127.4% above the low. LUNG is up 16.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 78.5%.

Pulmonx has posted a net loss over the last twelve months (EPS of -$1.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pulmonx

Company profile

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves.

Industry
Medical/Dental Instruments
CEO
Mr. Glendon E. French
Headquarters
Redwood City, CA
Employees
296
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Pulmonx generated $90.5 million in revenue, up 8.0% from fiscal 2024, its 7th consecutive year of revenue growth. Pulmonx reported a net loss of $54.0 million, compared with a loss of $56.4 million a year earlier. Gross margin was 74.2% (up from 74.0%) and operating margin -59.3%.

Pulmonx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$90.50M$83.79M$68.67M$53.66M$48.42M
Growth+8.01%+22.01%+27.98%+10.84%+47.91%
Net income$-54.00M$-56.39M$-60.84M$-58.92M$-48.66M
EPS (diluted)$-1.33$-1.44$-1.60$-1.59$-1.35

Analyst forecast

Forecast

Consensus (6 analysts)

none

Avg. price target

$4.25+65.37%

  • Strong buy 0
  • Buy 4
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $2.50High $7.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$-0.34 vs $-0.26
Surprise
-30.77%

LUNG news

All LUNG news

Pulmonx peers

Health Care sector
LUNG peer companies
CompanyPrice% ChgMarket capCompare
STIMNeuronetics Inc.1.25+0.81%$120.60Mvs LUNG
APYXApyx Medical Corporation2.40+0.42%$101.10Mvs LUNG
PYPDPolyPid Ltd.6.12-6.56%$129.29Mvs LUNG
KRMDKORU Medical Systems Inc.3.19-7.27%$138.37Mvs LUNG
NYXHNyxoah SA0.805-7.01%$81.98Mvs LUNG
SKINSkinHealth Systems Inc. Class A11.77-3.13%$76.68Mvs LUNG
LUCDLucid Diagnostics Inc.0.3727-3.52%$72.57Mvs LUNG
QTEXQTREX Quantum Ltd.1.00-10.71%$70.63Mvs LUNG

Indexes, lists and sector

Pulmonx stock FAQ

What is Pulmonx's stock price today?

LUNG last traded at $2.57 as of Nov 20, 4:00 PM EST, down 6.20% on the day. Prices are delayed at least 15 minutes.

Who is Pulmonx's CEO?

Mr. Glendon E. French is the chief executive officer of Pulmonx Corporation, which has about 296 employees.

What is the LUNG 52-week high?

The 52-week high for LUNG is $3.25 and the 52-week low is $1.13. The stock is currently 20.9% below its high.

Compare LUNG